PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
CONTENTS

PREFACE xi

ACKNOWLEDGMENTS xv

CONTRIBUTORS xvii

CHAPTER 1 INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS 1

1.1 Introduction 1

1.2 A Historical Perspective 2

1.2.1 Responses to Inhaled Compounds 3

1.2.2 Pharmaceutical Applications 3

1.2.3 Occupational and Environmental Applications 4

1.2.4 Digital Computation and PBPK Modeling 5

1.3 Expansion of PBPK Model Applications 6

1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data 7

1.3.2 Biological Mechanisms Underlying Pharmacokinetic Behaviors 8

1.3.3 Chemicals as Probes of Biological Processes 9

1.3.4 Risk Assessment Applications 10

1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response 12

1.4 Summary 13

Notation 14

References 15

PART I PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS

CHAPTER 2 HALOGENATED ALKANES 21

2.1 Introduction 21

2.2 PBPK Model Development for Volatile Organics 21

2.2.1 Model Formulation 22

2.2.2 Model Equations 23

2.2.3 Model Parameterization 25

2.2.4 Model Calculations 26

2.3 Experimental Methods Demonstrated for Groups of Chemicals 26

2.4 PBPK Models for Halogenated Alkanes 29

2.4.1 Anesthetic Gases 29
2.4.2 Chlorofluorocarbons (CFCs), Refrigerants, and Halons  31
2.4.3 Halogenated Alkanes  34
2.5 Summary  47
Notation  47
References  49

CHAPTER 3  HALOGENATED ALKENES  55
3.1 Introduction  55
3.2 The Chloroethylenes: Background  56
3.3 Review of PBPK Models  59
  3.3.1 Vinyl Chloride (VC)  59
  3.3.2 Vinyl Fluoride (VF)  61
  3.3.3 cis-1,2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE)  62
  3.3.4 Vinylidene Chloride (VDC)  63
  3.3.5 Trichloroethylene (TCE)  64
  3.3.6 Tetrachloroethylene (PERC)  69
  3.3.7 Allyl Chloride (AC)  72
  3.3.8 β-Chloroprene (CD)  73
  3.3.9 Hexachlorobutadiene, HCB  73
3.4 Summary  74
Notation  74
References  75

CHAPTER 4  ALKENE AND AROMATIC COMPOUNDS  79
4.1 Introduction  79
4.2 PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds  81
  4.2.1 Metabolism and Mode of Action  81
  4.2.2 Model Structures  82
  4.2.3 PK Differences  83
  4.2.4 Extrahepatic Metabolism and Transport of Metabolites  83
  4.2.5 GSH Conjugation  83
  4.2.6 Endogenous Production  84
  4.2.7 Reactivity with DNA and Protein  84
  4.2.8 Inhibition of Second Oxidative Steps  84
  4.2.9 Variability and PK Differences  84
  4.2.10 Subcompartments in PBPK Models  85
  4.2.11 “Privileged Access” of Epoxide Hydratase to Epoxide Substrates  85
4.3 Review of Aromatic and Alkene PBPK Models  85
  4.3.1 Benzene—A Known Human Carcinogen with an Uncertain Mode of Action  85
  4.3.2 Styrene—Early PBPK Models  90
  4.3.3 1,3-Butadiene  96
  4.3.4 Isoprene  101
  4.3.5 Ethylene, Propylene, and Their Oxides  102
  4.3.6 Naphthalene and Other PAHs  103
  4.3.7 Halobenzenes  105
  4.3.8 Miscellaneous Related Compounds  108
CHAPTER 5  REACTIVE VAPORS IN THE NASAL CAVITY

5.1 Introduction 119
  5.1.1 Nasal Effects and Risk Assessment 119
  5.1.2 General Models for Nasal Uptake 120
5.2 No Air-Phase Models 122
  5.2.1 The “Perfused Nose” Model 122
  5.2.2 Vinyl Acetate 124
5.3 Creating the Air-Phase Compartments 126
  5.3.1 Computational Fluid Dynamics 126
  5.3.2 Estimating the Air-Phase Mass Transfer Coefficient 126
  5.3.3 Estimating Air-Phase Mass Transfer Coefficients—Acrylic Acid 127
5.4 Other Models for Vapors Affecting Nasal Tissues 128
  5.4.1 Vinyl Acetate 128
  5.4.2 Ethyl Acrylate and Its Metabolite, Acrylic Acid 128
  5.4.3 Epichlorohydrin 131
5.5 Methyl Methacrylate 132
5.6 Formaldehyde 134
5.7 Hydrogen Sulfide 137
5.8 Summary 137
  Notation 138
  References 138

CHAPTER 6  ALKANES, OXYHYDROCARBONS, AND RELATED COMPOUNDS

6.1 Introduction 141
6.2 Purposes for PBPK Model Development 142
6.3 PBPK Models for Four Classes of Compounds 143
  6.3.1 Alkanes 143
  6.3.2 Oxyhydrocarbons 145
  6.3.3 Alkylbenzenes 155
  6.3.4 Siloxanes 160
6.4 Summary 162
  Notation 162
  References 163

PART II  PBPK MODEL DEVELOPMENT FOR ENVIRONMENTAL POLLUTANTS

CHAPTER 7  PESTICIDES AND PERSISTENT ORGANIC POLLUTANTS (POPs)

7.1 Introduction 169
7.2 Pesticides 172
  7.2.1 Chemical Classes of Pesticides 172
  7.2.2 Modeling Tissue Distribution 174
CHAPTER 11  ANTINEOPLASTIC AGENTS  297

11.1 Introduction  297
11.2 PBPK Models for Antineoplastic Agents  298
   11.2.1 Methotrexate  298
   11.2.2 cis-Dichlorodiammine-platinum  302
   11.2.3 Actinomycin D  305
   11.2.4 2’-Deoxycoformycin (Pentostatin)  306
   11.2.5 5-Fluorouracil  307
   11.2.6 2-Amino-1,3,4-thiadiazole  309
   11.2.7 1-β-d-Arabinofuranosylcytosine  309
   11.2.8 Adriamycin  310
   11.2.9 Melphalan  312
   11.2.10 Topotecan  313
   11.2.11 17-(Allylamino)-17-demethoxygeldanamycin  314
11.3 Summary  315
   Notation  315
   References  316

PART IV  PBPK MODELING APPROACHES FOR SPECIAL APPLICATIONS

CHAPTER 12  PERINATAL PHARMACOKINETICS  321

12.1 Introduction  321
12.2 Physiological and Biochemical Changes During Pregnancy  323
   12.2.1 Body Weight Changes and Organ Growth  323
   12.2.2 Physiological and Biochemical Changes in Pregnant Females  323
   12.2.3 Physiological Changes in Fetuses  326
   12.2.4 Mechanisms of Chemical Transfer Through Placenta  326
   12.2.5 Mechanisms of Chemical Transfer Through Breast Milk  327
12.3 Physiological Factors Incorporated into PBPK Models for Perinatal Pharmacokinetics  328
   12.3.1 Body Weight in the Mother  329
   12.3.2 Organ Volume and Cardiac Output in the Mother  329
   12.3.3 Chemical Transfer Through the Placenta and Mammary Gland  331
   12.3.4 Body Weight and Organ Volume in the Fetus/Pup  331
12.4 PBPK Models for Perinatal Transfer 333
   12.4.1 Tetracycline 333
   12.4.2 Morphine 333
   12.4.3 Theophylline 334
   12.4.4 Methadone 334
   12.4.5 Pethidine 334
   12.4.6 Trichloroethylene 335
   12.4.7 5,5’-Dimethyl-2,4-dione-oxazolidinedione (DMO) 335
   12.4.8 Tetrachloroethylene 335
   12.4.9 2-Methoxyethanol and Methoxyacetic Acid 336
   12.4.10 Methylmercury (MeHg) 338
   12.4.11 2,4-Dichlorophenoxyacetic Acid (2,4-D) 338
   12.4.12 Methanol 339
   12.4.13 Vitamin A Acid 339
   12.4.14 Organic Solvents 339
   12.4.15 p-Phenylbenzoic acid (PPBA) 340
   12.4.16 p,p’-Dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) 340
   12.4.17 2-Ethoxyethanol and Ethoxyacetic Acid 340
   12.4.18 Perchlorate 341
12.5 Risk Assessment Dosimetry Models 342
12.6 Summary 342
   Notation 343
   References 344

CHAPTER 13 MIXTURES 349

13.1 Introduction 349
13.2 PBPK Modeling of Chemical Mixtures 350
   13.2.1 Earlier Days: PBPK Modeling of Binary Mixtures 350
   13.2.2 More Recent Endeavor: PBPK Modeling of Higher-Order Mixtures 362
13.3 Future Perspectives: Second-Generation PBPK/PD Modeling 367
13.4 Summary 368
   Notation 369
   References 370

CHAPTER 14 DERMAL EXPOSURE MODELS 375

14.1 Introduction 375
14.2 Factors to Consider in Modeling Dermal Absorption 376
14.3 Dermal Absorption Models 378
   14.3.1 Membrane Models 378
   14.3.2 Compartment Models 379
14.4 Experimental Methods 383
14.5 Summary 384
   Notation 385
   References 385

CHAPTER 15 CONCLUSIONS AND FUTURE DIRECTIONS 389

15.1 Introduction 389
15.2 A Systems Approach for Pharmacokinetics 390
In recent years, there has been an enormous expansion of uses of physiologically based pharmacokinetic (PBPK) modeling in areas related to environmental chemicals and drugs. For individuals interested in PBPK modeling, it is relatively easy to locate and use the contributions of previous authors on a specific chemical of interest. However, it is more difficult to locate broader sets of contributions containing useful modeling techniques and applications. Our purpose was to provide a broad review of the PBPK modeling literature, before the size of the body of work grew large enough to make such an effort prohibitive, and to provide a resource to contain comprehensive coverage of the PBPK modeling literature from its beginnings in the mid-1900s through the first few years of the twenty-first century. This monograph is meant to be a useful reference and educational tool for those professionals and graduate students in toxicology, pharmacology, computational biology, and risk assessment interested in PBPK modeling as a tool for quantifying tissue doses and for describing the response of organisms to chemical exposures.

Our initial literature search in 2001 and updated in 2002, conducted using the Web of Science, Medline, and Toxline databases and incorporating keywords such as physiologically based pharmacokinetic/PBPK model, physiologically based toxicokinetic/PBTK model, and physiologically based pharmacodynamic/PBPD model, uncovered over 1000 references. As the term PBPK model did not become popular until the 1980s, for earlier contributions we relied on literature searches using the names of authors known by the editors to have made early contributions in the field, followed up by searches on other authors and articles cited in these articles. We chose to organize this diverse body of work based on classes of chemicals (e.g., volatile organics and environmental contaminants) and modeling purposes (e.g., perinatal transfer models and dermal absorption models). Our goal was to be fairly comprehensive, but to stress primary contributions in PBPK model development and in applications of these models to investigate factors that regulate chemical distribution within the body. We have also attempted to include articles that appeared over the past few years during completion of this volume. While we have made attempts to be inclusive in our coverage of the PBPK modeling literature, some important contributions may have been missed in our review process. We apologize to authors whose work may have been inadvertently overlooked in these various chapters and not captured by the editorial review.

This monograph describes the development of PBPK modeling for toxic compounds over the past eight decades and their current uses, providing background on the basics of PBPK modeling for understanding the physical, chemical, and biological properties that determine absorption, distribution, metabolism, and elimination of xenobiotics. Early PBPK modeling applications with volatile anesthetics and